证券研究报告 先声药业 (2096 HK) 港股通 SIM0500 获里程碑，年内有望 PoC | 华泰研究 | | 事件点评 | 投资评级(维持): | 买入 | | --- | --- | --- | --- | --- | | 2026 年 | 2 月 04 日│中国香港 | 生物医药 | 目标价(港币): | 19.82 | 2 月 3 日，公司公告其收到艾伯维就 SIM0500 的 4,000 万美元里程碑付款。 该分子临床开发合作进展积极，我们预计其有望年内读出 I 期临床数据。公 司已达成多项 10 亿美元级 BD 出海，创新研发体系与平台技术能力得到验 证。目前公司已授权产品开发进程稳步推进，先必新舌下片、NMTi 载荷 ADC 平台等有望成为下一轮出海重点，公司全球竞争力有望持续兑现。维持"买 入"。 预计临床 I 期开发顺利，有望年内数据读出 SIM0500 是公司自主开发的 BCMA/GPRC5D/CD3 三抗 TCE，于 2025 年 1 月授权艾伯维，现已获 FDA 的 FTD 认定。目前本品处于中美 I 期临床阶段， 国内剂量爬坡持续推进，美国于 2025 年中完成首例患者给药。本 ...

Investment Rating - The report maintains a positive outlook on Innovent Biologics, indicating an "Outperform" rating for the stock, expecting a relative return exceeding the benchmark index over the next 12-18 months [18]. Core Insights - In FY25, Innovent achieved total product revenue of approximately CNY 11.9 billion, representing a year-on-year increase of 45%, marking the first time the company surpassed the CNY 10 billion milestone [5][6]. - The oncology product portfolio has expanded to 13 products, with core products like Tyvyt® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [6][10]. - The chronic disease segment has seen significant commercialization results, with products such as mazdutide (GLP-1/GCG), tafolecimab (PCSK9), and teprotumumab (IGF-1R) driving revenue growth [7][9]. - In Q4 2025, total product revenue reached approximately CNY 3.3 billion, reflecting a 60% year-on-year increase, with six new drugs included in the National Reimbursement Drug List for 2026 [8][10]. - The company is progressing towards its revenue target of CNY 20 billion by 2027, with ongoing development in oncology, metabolism, autoimmune diseases, and ophthalmology [9]. Summary by Sections Financial Performance - Total product revenue for FY25 was approximately CNY 11.9 billion, a 45% increase year-on-year [5]. - Q4 2025 revenue was approximately CNY 3.3 billion, a 60% increase year-on-year [8]. Product Development - The oncology portfolio has expanded to 13 products, with core products maintaining steady growth [6]. - Significant commercialization in chronic diseases, with key products accelerating market uptake [7]. Market Position - The company is moving closer to its revenue target of CNY 20 billion by 2027, with a rich pipeline in various therapeutic areas [9].

Investment Rating - The report maintains a "Buy" rating for Geely Automobile [3][6] Core Insights - Geely's sales performance in January slightly exceeded industry expectations, with total sales of 270,200 units, a year-on-year increase of 1.3% [9] - The company's export sales saw significant growth, with January exports reaching 60,500 units, a year-on-year increase of 121.2% [9] - The report forecasts net profits for 2025-2027 to be 17.041 billion, 20.604 billion, and 24.318 billion yuan respectively, maintaining a target price of 23.37 HKD [3][5] Financial Summary - Revenue projections for 2023-2027 are as follows: 179.204 billion, 240.194 billion, 319.444 billion, 387.363 billion, and 448.685 billion yuan, with growth rates of 21.1%, 34.0%, 33.0%, 21.3%, and 15.8% respectively [5][10] - Operating profit is expected to grow from 3.806 billion yuan in 2023 to 23.173 billion yuan in 2027, with corresponding growth rates of 4.3%, 100.8%, 110.0%, 22.2%, and 18.1% [5][10] - The gross margin is projected to improve from 15.3% in 2023 to 17.3% in 2027 [10][11] - The report indicates a significant increase in the net profit attributable to the parent company, with a forecast of 5.308 billion yuan in 2023, rising to 24.318 billion yuan by 2027 [5][10]

本文是由投资/产品专员而非分析师撰写的文章汇编。 它不构成研究报告，也不应被解释为研究报告，也不旨在提供 专业、投资或任何其他类型的建议或推荐。 CSIWM 个股点评 2026 年 2 月 4 日 腾讯控股 本文内容由 Kylie Kwok (郭凯欣) 提供 中信证券财富管理(香港) 产品及投资方案部 中国互联网行业 电话：(852) 2237 9250 / 电邮：wminvestmentsolutions@citics.com.hk 摘要 中信证券财富管理与中信里昂研究观点一致。根据中信里昂研究在 2026 年 2 月 3 日发布的题为《Games keep strong momentum》的报告，腾讯预计将继续交出稳健业绩，2025 年第四季度总收入和调整后 Ebit 同比大幅增长。 分析指出，网络游戏有望带来积极惊喜并实现同比增长，得益于常青游戏的稳健表现以及新爆款游戏《三角洲行动》 的推动。尽管宏观环境疲弱，广告业务预计仍将同比增长，主要受广告技术升级和交易增长的支撑。随着毛利率扩张， 利润预计将继续快于收入增长。分析指出，腾讯在 2026 年有望维持双位数的游戏增长和广告增长，并被视为全球拥 有最优 ...

Investment Rating - The report maintains a positive outlook on Nissin Foods, indicating strong quarterly performance and consistent sales guidance for the fiscal year 2026 [4][5]. Core Insights - Nissin Foods reported robust quarterly results with sales of 213 billion JPY and operating profit of 21.6 billion JPY for Q3 FY2026, exceeding market expectations [4]. - The company’s sales in the U.S. market grew by 5%, marking the first positive growth in five quarters, which contributed to the overall positive market reaction [4]. - Nissin's overseas sales increased by 5.3% to 75.3 billion JPY, with the Americas showing an 8.4% growth, while the Chinese market experienced a decline of 2.3% [5]. Summary by Sections Financial Performance - For Q3 FY2026, Nissin Foods achieved sales of 213.3 billion JPY (up 4.5% year-on-year) and operating profit of 21.6 billion JPY (up 14.6% year-on-year), aligning with market expectations [4]. - The company maintained its full-year guidance, projecting sales of 792 billion JPY (up 2.0% year-on-year) and core operating profit of 68.5 billion JPY (down 18.0% year-on-year) [5]. Business Segments - Nissin's overseas business, including the Americas, China, Asia, and EMEA, reported a sales increase of 5.3% to 75.3 billion JPY, with a notable operating profit margin of 12.8% [5]. - The U.S. market's sales growth was driven by a 3.8% same-store sales increase, while the Brazilian market also saw a 5% increase [5]. Market Position - As of February 3, 2026, Nissin Foods' stock price was 3,253 JPY, with a market capitalization of 5.57 billion USD [10]. - The company has a strong asset base of 812 billion JPY and is focused on maintaining a significant share of its sales from domestic operations [8].

Investment Rating - The investment rating for the company is "Buy" with a current price of 92.15 HKD and a target value of 133.47 HKD [3]. Core Insights - The report anticipates that the company's revenue for 2025 will reach 365.3 billion RMB, with an adjusted net profit loss of 22.5 billion RMB. The company is expected to maintain a strong operational barrier in the takeaway business, despite short-term profit pressures due to competition [6][13]. - The report highlights that the competition in the instant retail business is easing, with a projected order volume growth of 30% for flash purchases in Q4 2025. However, the takeaway business is expected to face continued competition, particularly in high-value orders [6][7][8]. Financial Forecast - Revenue projections for the company are as follows: - 2023: 276.74 billion RMB - 2024: 337.59 billion RMB (growth rate: 25.82%) - 2025: 365.32 billion RMB (growth rate: 8.21%) - 2026: 414.90 billion RMB (growth rate: 13.57%) - 2027: 467.34 billion RMB (growth rate: 12.64%) [6]. - The adjusted net profit forecast indicates losses for 2025 and 2026, with expected losses of 22.5 billion RMB and 7.2 billion RMB, respectively [6][13]. Business Segment Performance - Core local business revenue is projected to be 643.92 billion RMB in Q4 2025, with a year-over-year decline of 1.79% and an operational loss of 111.16 billion RMB [7][9]. - New business revenue is expected to reach 270.46 billion RMB in Q4 2025, reflecting an 18% year-over-year growth, although operational losses are projected at 42.78 billion RMB [8][9]. Valuation Methodology - The report employs a sum-of-the-parts (SOTP) valuation method, estimating the company's fair value at 133.47 HKD per share, based on contributions from various business segments including takeaway, in-store travel, flash purchases, and new businesses [13][14].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 12.89 per share, indicating a potential upside of 37.2% from the current price of HKD 9.40 [1][6]. Core Insights - The company anticipates a significant increase in net profit for 2025, projected to rise by 400% to 450% compared to the previous year, driven by strong demand in non-mobile sectors, a focus on high-end products, and gains from the sale of a subsidiary [3][9]. - The product structure of camera modules is being optimized, with a notable increase in average selling prices, reflecting a shift towards high-end camera modules [4][10]. - The non-mobile camera module business is emerging as a new growth driver, with sales in automotive and IoT applications showing substantial growth [5][14]. Financial Projections - Revenue forecasts for 2025 to 2027 are estimated at RMB 198.04 billion (+22.6%), RMB 219.53 billion (+10.9%), and RMB 244.77 billion (+11.5%) respectively, with net profit projections of RMB 14.26 billion (+411%), RMB 9.1 billion (-36.2%), and RMB 10.92 billion (+17.8%) [6][19]. - The average gross margin is expected to improve, reflecting the company's strategic focus on higher-value products [7][19]. Market Position and Strategy - The company is enhancing its vertical integration in the smart vision system sector, with investments in technology and partnerships aimed at expanding capabilities in smartphones, IoT, and emerging markets [21][20]. - The company has established partnerships with leading automotive brands and smart driving solution providers, indicating a strategic shift towards non-mobile applications [5][14].

Investment Rating - The report maintains a "Buy" rating for Geely Automobile [3][6] Core Views - Geely's sales performance in January slightly exceeded industry expectations, with total sales of 270,200 units, a year-on-year increase of 1.3% [9] - The company's "oil-electric hybrid" strategy has shown significant results, with January sales of new energy vehicles reaching 124,300 units, a year-on-year increase of 2.6% [9] - Exports have seen substantial growth, with January exports reaching 60,500 units, a year-on-year increase of 121.2% [9] - The Zeekr brand has achieved success in the high-end market, with Zeekr 9X becoming the best-selling large SUV in its price range [9] Financial Forecasts and Investment Recommendations - The forecast for net profit attributable to the parent company for 2025-2027 is 17.041 billion, 20.604 billion, and 24.318 billion yuan respectively, maintaining a target price of 20.79 yuan (RMB) or 23.37 Hong Kong dollars [3] - Revenue projections for 2023-2027 are 179.204 billion, 240.194 billion, 319.444 billion, 387.363 billion, and 448.685 billion yuan, with growth rates of 21.1%, 34.0%, 33.0%, 21.3%, and 15.8% respectively [5][10] - Operating profit is expected to grow significantly, with projections of 3.806 billion, 7.644 billion, 16.055 billion, 19.616 billion, and 23.173 billion yuan for the same period [5][10] - The report indicates a consistent improvement in gross margin, projected to reach 17.3% by 2027 [10]

Investment Rating - The report maintains a "Buy" rating for WuXi AppTec (2268.HK) with a target price of HKD 75, indicating a potential upside of 24% from the current price of HKD 60.6 [1][2][11]. Core Insights - The company's preliminary earnings forecast for 2025 shows revenue growth exceeding 45% year-on-year, with gross profit growth over 70% and net profit growth exceeding 38% [8][11]. - WuXi AppTec has signed 70 new iCMC projects in 2025, benefiting from strong growth in the US and China, with over half of these projects coming from new ADC contributions [8][11]. - The company has provided a long-term revenue guidance of a 30-35% CAGR from 2025 to 2030, which is above the industry average of 25.6% CAGR [8][11]. Financial Performance - Revenue projections for 2025, 2026, and 2027 are adjusted to RMB 58.7 billion, RMB 79.4 billion, and RMB 105.9 billion respectively, with net profit estimates of RMB 16.0 billion, RMB 21.2 billion, and RMB 29.1 billion [11][12]. - The gross margin for 2025 is expected to be around 35.8%, which is better than previous expectations [8][11]. - The company anticipates significant commercial revenue starting in 2027, with limited contributions expected in 2026 as it focuses on accumulating production records [8][11]. Capacity Expansion - WuXi AppTec is accelerating capacity expansion through both self-built facilities and acquisitions, with capital expenditures expected to rise to RMB 1.7 billion in 2026 from RMB 1.22 billion in 2025 [2][10]. - The company has established dual production bases in China and Singapore, with plans for further expansion, including new DP production lines in Wuxi and a new facility in Singapore expected to achieve GMP release in 2026 [2][10]. - The company has a global market share of over 24% in the ADC outsourcing service market, indicating a strong competitive position [10].

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [4]. Core Insights - The company, Leshu Shi, is a leading player in the African hygiene products market, specializing in baby diapers and sanitary napkins, with the highest market share in both categories. The African market benefits from a demographic dividend and low penetration rates in these product categories, indicating significant growth potential. The company's strong localization capabilities are expected to drive long-term stable growth as it expands its distribution channels and product categories in Africa and replicates its operational model in other emerging markets [5][15]. Financial Summary - The company’s revenue is projected to grow from $411 million in 2023 to $712 million by 2027, with a compound annual growth rate (CAGR) of 19.2% from 2022 to 2024. The net profit is expected to increase from $65 million in 2023 to $154 million in 2027, with a CAGR of 127.4% during the same period. The gross margin is forecasted to remain stable around 35% [8][21][25]. Product and Market Positioning - Leshu Shi has developed a multi-brand strategy with a diverse product matrix, including four major brands in the baby care segment and three in the women's care segment. The company has a total of 263 SKUs for baby diapers and 44 for sanitary napkins, catering to various local needs. The company maintains the leading sales market share in Africa for both product categories, with significant growth rates outpacing competitors [6][15]. Production and Distribution Capabilities - The company operates eight factories across eight African countries, with a focus on local production to enhance cost efficiency. It has established a deep distribution network that covers over 30 countries, reaching more than 80% of the local population. This extensive network and understanding of local markets provide a competitive edge over international brands [7][15]. Regional Performance - Revenue growth varies by region, with West Africa showing stable growth, East Africa as a high-growth area, and Central Africa experiencing rapid expansion. Latin America is emerging as a new growth engine, with revenue increasing significantly from $0.004 million in 2022 to $0.09 million in 2024 [31][35][38]. Cash Flow and Liquidity - The company has seen a substantial increase in operating cash flow, rising from $0.14 million in 2022 to $1.10 million in 2024, with a CAGR of 184.1%. Cash and cash equivalents have also grown from $0.22 million to $0.31 million during the same period, indicating improved liquidity and financial stability [42][44].